Northern Trust Corp Buys 51,926 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Northern Trust Corp raised its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 9.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 627,649 shares of the company's stock after purchasing an additional 51,926 shares during the quarter. Northern Trust Corp owned about 1.05% of Twist Bioscience worth $29,167,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of TWST. Van ECK Associates Corp raised its holdings in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after acquiring an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience during the 3rd quarter worth about $34,000. US Bancorp DE raised its stake in shares of Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after purchasing an additional 601 shares in the last quarter. KBC Group NV lifted its holdings in shares of Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after buying an additional 1,226 shares during the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Twist Bioscience by 19.9% in the 4th quarter. Blue Trust Inc. now owns 4,567 shares of the company's stock valued at $206,000 after buying an additional 757 shares in the last quarter.

Twist Bioscience Stock Performance

TWST traded down $2.77 during trading on Wednesday, reaching $29.52. 1,544,079 shares of the company's stock were exchanged, compared to its average volume of 969,604. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The business has a 50 day moving average price of $38.31 and a 200 day moving average price of $43.56. Twist Bioscience Co. has a fifty-two week low of $29.27 and a fifty-two week high of $60.90. The company has a market capitalization of $1.77 billion, a P/E ratio of -8.73 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. As a group, analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on TWST. Robert W. Baird cut their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. The Goldman Sachs Group decreased their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. JPMorgan Chase & Co. lowered their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Guggenheim reissued a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. Finally, Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $50.40.

Insiders Place Their Bets

In related news, SVP Paula Green sold 918 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the completion of the sale, the senior vice president now owns 130,912 shares in the company, valued at $5,355,609.92. This trade represents a 0.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Emily M. Leproust sold 2,402 shares of the company's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the sale, the chief executive officer now directly owns 662,692 shares in the company, valued at $27,110,729.72. This represents a 0.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,991 shares of company stock worth $742,654 over the last three months. 3.01% of the stock is currently owned by corporate insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.